Publications by the researcher in collaboration with Felipe Casanueva Freijo (33)

2017

  1. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement

    Pituitary, Vol. 20, Núm. 5, pp. 489-498

2016

  1. β-Arrestin scaffolds and signaling elements essential for the obestatin/GPR39 system that determine the myogenic program in human myoblast cells

    Cellular and Molecular Life Sciences, Vol. 73, Núm. 3, pp. 617-635

2015

  1. Action of obestatin in skeletal muscle repair: Stem cell expansion, muscle growth, and microenvironment remodeling

    Molecular Therapy, Vol. 23, Núm. 6, pp. 1003-1021

2012

  1. The obestatin/GPR39 system is up-regulated by muscle injury and functions as an autocrine regenerative system

    Journal of Biological Chemistry, Vol. 287, Núm. 45, pp. 38379-38389

2006

  1. Effect of acute ghrelin administration on glycaemia and insulin levels in obese patients

    Diabetes, Obesity and Metabolism, Vol. 8, Núm. 5, pp. 555-560

2004

  1. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients

    Clinical Endocrinology, Vol. 61, Núm. 2, pp. 250-255

2003

  1. Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese hypopituitary patients

    European Journal of Endocrinology, Vol. 149, Núm. 2, pp. 117-122

  2. Diagnosis of growth hormone deficiency after pituitary surgery: The combined acipimox/GH-releasing hormone test

    Clinical Endocrinology, Vol. 58, Núm. 2, pp. 156-162

  3. Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients

    Clinical Endocrinology, Vol. 59, Núm. 4, pp. 431-436

2002

  1. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity

    Clinical Endocrinology, Vol. 56, Núm. 4, pp. 487-492

  2. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome

    Clinical Endocrinology, Vol. 57, Núm. 6, pp. 745-749

2001

  1. Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients

    Clinical Endocrinology, Vol. 54, Núm. 4, pp. 509-513

2000

  1. Sanidade: a medicina de Galicia en movemento, 2000-2010

    Galicia 2010 (Asociación Proxecto de Investigación Galicia 2010), pp. 209-238

1999

  1. Prevalence of pregnancy and postpartum thyroid dysfunction in a homogeneous population of Spain

    Gynecological Endocrinology, Vol. 13, Núm. 4, pp. 279-287

  2. Regulation of growth hormone secretion by signals produced by the adipose tissue

    Journal of Endocrinological Investigation, Vol. 22, Núm. 5 SUPPL., pp. 22-26

  3. Serum leptin levels in women throughout pregnancy and the postpartum period and in women suffering spontaneous abortion

    Clinical Endocrinology, Vol. 50, Núm. 2, pp. 211-216

  4. The use of growth hormone (GH) secretagogues in the diagnosis of GH deficiency in humans

    Growth Hormone and IGF Research

1998

  1. Acute changes in free-fatty acids (FFA) do not alter serum leptin levels

    Journal of Endocrinological Investigation, Vol. 21, Núm. 8, pp. 526-530

  2. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism

    Journal of Clinical Endocrinology and Metabolism, Vol. 83, Núm. 12, pp. 4350-4354

1996

  1. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli

    Journal of Clinical Endocrinology and Metabolism, Vol. 81, Núm. 3, pp. 909-913